OVX group. In the TPTD and ALN group, the expression levels of TNF-α was significantly degreased than the OVX group. And the expression levels of TNF-α was no significance between the TPTD and ALN group. Conclusions: In this study, TPTD and ALN treatments prevented bone loss in OVX mice. Mechanical hyperalgesia in hindlimbs tended to be decreased in the OVX group compared with the TPTD and ALN group. ALN treatment was more effective in bone formation compared with TPTD treatment, whereas pain relief was no significance between TPTD and ALN treatment. These results suggest that TPTD treatment was more effective in osteoporosis patients with skeletal pain. Background: Patients with rheumatic diseases (RD) have an increased risk of developing osteoporosis (OP) compared with healthy population due to chronic inflammation, low physical activity and using some kind of medications. Persons with RD and OP require prolonged osteoporosis treatment due to increased risk of fracture. Objectives: To evaluate adherence and persistence with different osteoporosis medications in RD patients with OP during 3 years. Methods: We conducted a retrospective study of 204 patients (82% women, mean age 54±11 years) with RD (93 -rheumatoid arthritis, 48 -systemic sclerosis, 39 -systemic lupus erythematosus and 24 -ankylosing spondylitis), whom OP was diagnosed in 2013. In 2016 we revised there medical charts for collection information on the osteoporosis treatment and performed telephone contact for patient's self-reporting. Results: 196 (96%) patients started the OP treatment. Among them 26% -alendronate, 24% received alfacalcidol or supplements of calcium and vitamin D only, 16% -stroncium ranelate, 12% -ibandronate, 9% zoledronic acid, 8% -calcitonin and 5% -denosumab. 8 (4%) patients didn't start the drug treatment at all, 72 (35%) patients were persisted less than 12 months, 47 (23%) -2 years and 77 (38%) -3 years. Mean persistence was 2.1, 2.4, 1.6, 1.7, 1.9, 2.0 years for alendronate, alfacalcidol, stroncium ranelate, ibandronate, zoledronic acid, denosumab, respectively. 61 (31%) persons were switched from one antiosteoporotic medication to another due to side effects, inconvenient dose regimen or other reasons. Persistence to oral therapy was better among women than men (p<0.05), especially on daily regimen. Discontinuers were less likely than persistent subjects to visit rheumatologist and BMD measurement each year for control of treatment (p<0.05). Patients with ankylosing spondylitis were less persistent than persons with other RD. Presence of OP fractures in anamnesis had no significant influence on adherence. 8 (4%) patients had fractures during retrospective period, among them 6 -received only supplements of calcium and vitamin D, 1 -zoledronic acid once and 1 -without OP therapy. Conclusions: Only 1/3 of patients with RD received antiosteoporotic drugs during 3 years. Visits to rheumatologist and BMD measurements increased subject's persistence. Improving the quality of medical care can be achieved through education and motivation of patients for a long-term treatment of OP. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.2422 
FRI0568 ECHOSOUND APPROACH FOR SHORT-TERM FOLLOW-UP OF THE DENOSUMAB EFFECT ON BMD RECOVERY AGAINST AROMATASE INHIBITOR IMPACT IN BREAST CANCER PATIENTS
Background: Systemic sclerosis (SSc) is a rare connective tissue disorder characterized by an increased synthesis and deposition of extracellular matrix in the skin and internal organs (1). Several studies described SSc as potential risk factor for osteoporosis, however, to date the bone quality in SSc is unclear (2). Trabecular bone score (TBS) has been recently proposed as an indirect measure of bone microarchitecture (3). Objectives: The aim of this study was to assess bone microarchitecture in SSc patients and possible association with disease severity and microangiopathy. Methods: Twenty-three female SSc patients (mean age 63.2±12.8 SD years, mean disease duration 92.8±66 SD months, mean Raynaud's Phenomenon duration 142.6±126.1 SD months) were enrolled after written informed consent. The assessment of disease severity was performed using the Medsger's severity scale (4). Bone Mineral Density (BMD) measurements at L1-L4, femoral neck and total hip, were performed using DXA Prodigy Densitometer (GE Lunar). TBS was derived for each spine DXA examination using the TBS index (TBS iNsight Medimaps). Nailfold videocapillaroscopy (NVC) was used to assess the microangiopathy based on nailfold video capillaroscopic pattern (NVC) analysis and the microangiopathy evolution score (MES) (5-6). Using the FRAX (Fracture Risk Assessment Tool) we also evaluate the 10-year risk of hip and major joints osteoporotic fracture. Results: A positive correlation was observed between TBS and Medsger's general organ score (r=0.5; p=0.01); no other correlations were found between TBS and Medsger's score. Interestingly, TBS was positively and significantly correlated with modified Rodnam skin score (mRss) (p=0.01). When the patients were divided in two groups considering skin involvement by mRss, TBS was found significantly higher into the group with mRss >15 compared to the group with mRss <15 (1.255±0.08 vs 1.163±0.03; p=0.01) No correlations were found between NVC patterns/MES and bone quality assessment (TBS) or bone density assessment (BMD), only a significant correlation, as expected, was observed
